MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.06.13.26355379

Медицинская библиотека · medRxiv : the preprint server for health sciences · 2026

The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.

Yasui Daisuke, Weatherill Daniel, Dugom Laura, Weiner Sophia, Gopalakrishnan Lathika, Tran Huy, Oskarsson Björn, Nagle Kyra, Miller Timothy, Gutierrez Gilbert, Ravits John, Hoover Benjamin, Harms Matthew, Shneider Neil, Neylon Lizzi, Dailey Whitney, Ladha Shafeeq, Holmes Cassandra, Lee Joseph, Streicher Nicholas, Nayar Shakti, Harris Brent T, Raisinghani Manish, Zetterberg Henrik, Gobom Johan, Easton Amy, Bowser Robert, Ly Cindy V

СтатьяПрепринтПеревод пока не подготовлен

Аннотация

Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease of motor neurons for which therapeutics are limited. Improved biomarkers are imperative to improve patient care and therapeutic development. Here, we employed 35-plex isobaric tandem mass tag labeling based on isobutyl-proline reporter group (TMTpro) to perform unbiased proteomic analysis of cerebrospinal fluid (CSF) and plasma from control (n= 28, n= 31) and sporadic ALS (sALS) (n= 39, n= 41), from the Target ALS Global Natural History Study (TALS GNHS). We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform. This initial cross-sectional proteomic study of biofluids from the TALS GNHS, with unrestricted availability of study results to the research community, highlights the potential of this resource as a potent platform for ALS biomarker discovery.

Для цитирования: Yasui Daisuke, Weatherill Daniel, Dugom Laura, Weiner Sophia, Gopalakrishnan Lathika, Tran Huy, Oskarsson Björn, Nagle Kyra, Miller Timothy, Gutierrez Gilbert, Ravits John, Hoover Benjamin, Harms Matthew, Shneider Neil, Neylon Lizzi, Dailey Whitney, Ladha Shafeeq, Holmes Cassandra, Lee Joseph, Streicher Nicholas, Nayar Shakti, Harris Brent T, Raisinghani Manish, Zetterberg Henrik, Gobom Johan, Easton Amy, Bowser Robert, Ly Cindy V. The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.. medRxiv : the preprint server for health sciences. 2026. DOI: 10.64898/2026.06.13.26355379.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.